Salmeterol fluticasone propionate: A review of its use in asthma

Drugs

Volumn 69, Issue 13, 2009, Pages 1799-1828

  McKeage, Kate ^a   Keam, Susan J ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; KETOCONAZOLE; LONG ACTING BETA2 ADRENOCEPTOR AGONIST; METHACHOLINE; MONTELUKAST; PLACEBO; RITONAVIR; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; AREA UNDER THE CURVE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPHONIA; EAR INFECTION; EVENING DOSAGE; EXERCISE; FORCED EXPIRATORY VOLUME; HOARSENESS; HOSPITALIZATION; HUMAN; INFLUENZA; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; METERED DOSE INHALER; MONOTHERAPY; MORNING DOSAGE; NOSE INFECTION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHARYNGITIS; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SINUSITIS; SUSTAINED DRUG RELEASE; SYMPTOM; SYSTEMATIC REVIEW; THROAT IRRITATION; THRUSH; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS;

EID: 69749122319     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11202210-000000000-00000     Document Type: Review

References (111)

1. Jeffery P. Inflammation and remodeling in the adult and child with asthma. Pediatr Pulmonol 2001; 21 Suppl.: 3-16
2. Masoli M, Fabian D, Holt S, et al. Global burden of asthma. Developed for the Global Inititive for Asthma [online]. Available from URL: http://www.ginasthma.com/ReportItem.asp?1I=2=94 [Accessed 2009 May 29]
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. GINA report: global strategy for asthma management and prevention (updated 2007) [online]. Available from URL: http://www.ginasthma.com/ Guidelineitem.asp?1=212=1Id=1561 [Accessed 2009 Apr 28]
4. Reynolds NA, Lyseng-Williamson KA, Wiseman LR. In- haled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs 2005; 65 (12): 1715-34
5. Adkins JC, McTavish D. Salmeterol: a review of its phar- macological properties and clinical efficacy in the management of children with asthma. Drugs 1997; 54 (2): 331-54
6. Jarvis B, Faulds D. Inhaled fluticasone propionate: a re- view of its therapeutic efficacy at dosages 500 jj,g/day in adults and adolescents with mild to moderate asthma. Drugs 1999; 57 (5): 769-803
7. Wolters Kluwer Adis. R&D Insight. Salmeterol/fluticasone propionate: product information [online]. Available from URL: http://bi.adisinsight.com/ frames.aspx [Accessed 2009 May 25]
8. Kirby S, Falcoz C, Daniel MJ, et al. Salmeterol and fluti- casone propionate given as a combination: lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001; 56: 781-91
9. Chung KF, Adcock IM. Combination therapy of long- acting B2-adrenoceptor agonists and corticosteroids for asthma. Treat Respir Med 2004; 3 (5): 279-89
10. Koopmans JG, Lutter R, Jansen HM, et al. Adding sal- meterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax 2006 Apr; 61 (4): 306-13
11. Houghton CM, Lawson N, Borrill ZL, et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respir Res 2007; 8: 52
12. Palmqvist M, Arvidsson P, Beckman O, et al. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14: 29-34
13. Aldington S, Williams M, Weatherall M, et al. Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: a randomized controlled trial in childhood asthma. Respirology 2006 Sep; 11 (5): 638-42
14. Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006 Oct; 118 (4): 809-16
15. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370: 2118-25
16. Bleecker ER, Nelson H, Corren J, et al. Arg16Gly poly- morphism of the beta-(2)-adrenergic receptor gene does not modulate clinical response to salmeterol in subjects with asthma [abstract no. 554]. J Allergy Clin Immunol 2008 Feb; 121 (2): S143
17. Ortega H, Klotsman M, Yancey S, et al. Associations be- tween genetic polymorphisms and withdrawals from controlled clinical trials in Caucasian and African American patients with asthma [abstract no. F24 plus poster]. Am J Respir Crit Care Med 2007 Apr 1; 175: A462
18. Kawai M, Kempsford R, Pullerits T, et al. Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics. Respir Med 2007 Dec; 101 (12): 2488-94
19. Bailey W, Castro M, Matz J, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opin 2008 Jun; 24 (6): 1669-82
20. GlaxoSmithKline. Advair Diskus® 100/50, 250/50, 500/50 prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us- advair.pdf [Accessed 2009 May 24]
21. European Medicines Agency. Seretide Diskus® 50/100, 50/250, 50/500 microgram dose inhalation powder [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/referral/seretideevohaler/ SeretideEvohalerAnnexes%20I-II-II-en.pdf [Accessed 2009 Apr 3]
22. Strand AM, Luckow A. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respir Med 2004 Oct; 98 (10): 1008-15
23. Bergmann K-C, Lindemann L, Braun R, et al. Salmeterol/ fluticasone propionate (50/250 (J.g) combination is superior to double dose fluticasone (500 (J.g) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 2004 Jan 24; 134 (3-4): 50-8
24. Lundback B, Ronmark E, Lindberg A, et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med 2006 Jan; 100 (1): 2-10
25. Godard P, Greillier P, Pigearias B, et al. Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study. Respir Med 2008 Aug; 102 (8): 1124-31
26. Fitzgerald J-M, Boulet L-P, Follows RMA. The CON- CEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of for-moterol/budesonide in adults with persistent asthma. Clin Ther 2005 Apr; 27 (4): 393-406
27. Dahl R, Chuchalin A, Gor D, et al. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med 2006 Jul; 100 (7): 1152-62
28. Adachi M, Aizawa H, Ishihara K, et al. Comparison of salmeterol/ fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients. Respir Med 2008 Jul; 102 (7): 1055-64
29. Papi A, Paggiaro P, Nicolini G, et al. Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007 Oct; 62(10): 1182-8
30. Jarjour NN, Wilson SJ, Koenig SM, et al. Control of air- way inflammation maintained at a lower steroid dose with 100/50 (J.g of fluticasone propionate/salmeterol. J Allergy Clin Immunol 2006 Jul; 118 (1): 44-52
31. de Blic J, Ogorodova L, Klink R, et al. Salmeterol/ fluticasone propionate vs double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol. Epub 2009 Feb 20
32. Van den Berg NJ, Ossip MS, Hederos CA, et al. Salme- terol/fluticasone propionate (50/100 jxg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma. Pediatr Pulmonol 2000; 30: 97-105
33. Maspero J, Guerra F, Cuevas F, et al. Efficacy and toler- ability of salmeterol/fluticasone propionate versus mon-telukast in childhood asthma: a prospective, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2008 Aug; 30 (8): 1492-504
34. American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007 May 17; 356 (20): 2027-39
35. Pearlman D, Qaqundah P, Matz J, et al. Fluticasone pro- pionate/salmeterol and exercise-induced asthma in children with persistent asthma. Pediatr Pulmonol 2009; 44 (5): 429-35
36. Gappa M, Zachgo W, von Berg A, et al. Superior efficacy of the salmeterol/fluticasone 50(j.g/100(j.g combination compared to fluticasone 200 (J.g in children with uncontrolled asthma: the VIAPAED trial [abstract no. 3057]. 18th Annual Congress of the European Respiratory Society; 2008 Oct 4-8; Berlin
37. Woodcock AA, Bagdonas A, Boonsawat W, et al. Improve- ment in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone. Prim Care Respir J 2007 Jun; 16 (3): 155-61
38. Pedersen SE, Bateman ED, Bousquet J, et al. Determinants of response to fluticasone propionate and salmeterol/ fluticasone propionate combination in the Gaining Optimal Asthma controL study. J Allergy Clin Immunol 2007 Nov; 120 (5): 1036-42
39. Lundback B, Ronmark E, Lindberg A, et al. Asthma con- trol over 3 years in a real-life study. Respir Med 2009 Mar; 103 (3): 348-55
40. Stanford RH, Fuhlbrigge A, Riedel A, et al. An observa- tional study of fixed dose combination fluticasone pro-pionate/salmeterol or fluticasone propionate alone on asthma-related outcomes. Curr Med Res Opin 2008 Oct; 24 (11): 3141-8
41. O'Connor RD, Carranza Rosenzweig JR, Stanford RH, et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann Allergy Asthma Immunol 2005 Dec; 95 (6): 535-40
42. Nguyen WT, Stewart C, Fisher K, et al. Maintenance asthma treatment with fluticasone/salmeterol combination via Diskus: effect on outcomes in inner-city children enrolled in TennCare. Allergy Asthma Proc 2005 Mar-Apr; 26 (2): 129-34
43. O'Connor RD, Stanford RH, Yeh W, et al. Observational study of the association of fluticasone propionate/salmeterol via a single device and inhaled corticosteroid use in children on asthma related emergency department and hospitalization visits [abstract no. 22]. J Allergy Clin Immunol 2008 Feb; 121 Suppl. 2A: 6
44. Delea TE, Stanford RH, Hagiwara M. Observational study of outcomes with fluticasone propionate (FP)/salmeterol in a single device vs. doubling the dose of FP in asthma patients not adequately controlled with FP alone [abstract no. C32]. Am J Respir Crit Care Med 2008 May 16; 177: A609
45. Wang M-T, Skrepnek GH, Armstrong E, et al. Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitali-zation among patients with asthma. Curr Med Res Opin 2008; 24 (3): 859-67
46. Chan J, Hui RL, Spence MM. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids. J Manag Care Pharm 2007 Jan; 13 (1): 21-7
47. Barnes NC, Jacques L, Goldfrad C, et al. Initiation of maintenance treatment with salmeterol/fluticasone pro-pionate 50/100mg bd versus fluticasone propionate 100 mg bd alone in patients with persistent asthma: integrated analysis of four randomised trials. Respir Med 2007 Nov; 101 (11): 2358-65
48. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008 Jul; 149 (1): 33-42
49. Nelson HS, Chapman KR, Pyke SD, et al. Enhanced sy- nergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003 Jul; 112 (1): 29-36
50. Ortega H, Jain R, Emmett A. Subjects receiving fluticasone propionate/salmeterol 100/50 mcg BID have significantly fewer asthma attacks vs montelukast 10mg QD +/- fluti-casone propionate 100 mcg BID: retrospective analysis of 4 randomized studies [abstract no. F80 plus poster]. Am J Respir Crit Care Med 2007 Apr; 175 Suppl.: A495
51. GlaxoSmithKline. Sponsor Briefing Statement. Advair Dis- kus, Advair HFA. inhalation aerosol, Serevent, Servevent Diskus [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-04-GSK.pdf [Accessed 2009 Jul 14]
52. Murray J, Rosenthal R, Somerville L, et al. Fluticasone pro- pionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting b2-agonists. Ann Allergy Asthma Immunol 2004 Oct; 93 (4): 351-9
53. Nelson HS, Wolfe JD, Gross G, et al. Efficacy and safety of fluticasone propionate 44 mg/salmeterol 21 mg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Ann Allergy Asthma Immunol 2003 Sep; 91 (3): 263-9
54. Rojas RA, Paluga I, Goldfrad CH, et al. Initiation of main- tenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate. J Asthma 2007 Jul; 44 (6): 437-41
55. Bateman ED, Boushey HA, Bousquet J, et al. Can guide- line-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 2004 Oct; 170 (8): 836-44
56. Calhoun WJ, Nelson HS, Nathan RA, et al. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting b2-agonists alone. Am J Respir Crit Care Med 2001 Sep; 164: 759-63
57. Pearlman DS, White MV, Lieberman AK, et al. Flutica- sone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol 2002 Feb; 88: 227-35
58. Kerwin EM, Nathan RA, Meltzer EO, et al. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. Respir Med 2008 Apr; 102 (4): 495-504
59. Nathan RA, Rooklin A, Schoaf L, et al. Efficacy and toler- ability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clin Ther 2006 Jan; 28 (1): 73-85
60. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 (J.g and fluticasone propionate 250 (J.g in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527-34
61. Busse W, Koenig SM, Oppenheimer J, et al. Steroid-sparing effects of fluticasone propionate 100 (J.g and salmeterol 50 (J.g administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 (J.g administered twice daily. J Allergy Clin Immunol 2003 Jan; 111 (1): 57-65
62. Weiler JM, Nathan RA, Rupp NT, et al. Effect of fluticaso- ne/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Ann Allergy Asthma Immunol 2005 Jan; 94 (1): 65-72
63. Stauffer J, Watikus-Edwards K, Yancey S, et al. Flutica- sone propionate/salmeterol administered via Diskus® provides protection against activity-induced bronchospasm in children and adolescents with persistent asthma [abstract no. P103]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A62
64. Aubier M, Pieters WR, Schlosser NJJ, et al. Salmeterol/ fluticasone propionate (50/500 (J.g) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876-84
65. Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999 Jan; 6 (1): 45-51
66. Bateman ED, Britton M, Carrillo J, et al. Salmeterol/ fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998; 16 (3): 193-201
67. Ringdal N, Eliraz A, Pruzinec P, et al. The salmeterol/ fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003 Mar; 97: 234-41
68. Nelson HS, Busse WW, Kerwin E, etal. Fluticasone propionate/ salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000 Dec; 106 (6): 1088-95
69. Jenkins C, Woolcock AJ, Saarelainen P, et al. Salmeterol/ fluticasone propionate combination therapy 50/250 (J.g twice daily is more effective than budesonide 800 (J.g twice daily in treating moderate to severe asthma. Respir Med 2000; 94: 715-23
70. Johansson G, McIvor RA, D'Ambrosio FP, et al. Com- parison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma. Clin Drug Invest 2001; 21 (9): 633-42
71. Bousquet J, Boulet LP, Peters MJ, et al. Budesoni- de/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med 2007 Dec; 101 (12): 2437-46
72. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesoni- de/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007 May; 61 (5): 725-36
73. Aalbers R, Backer V, Kava TTK, et al. Adjustable main- tenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20 (2): 225-40
74. Ringdal N, Chuchalin A, Chovan L, et al. Evaluation of dif- ferent inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide™ (50/250 (J.g bd Diskus™ vs. formoterol (12jj,g bd) and budesonide (800 (J.g bd) given concurrently (both via Turbuhaler™) in patients with moderate-to-severe asthma. Respir Med 2002 Nov; 96: 851-61
75. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/ formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26 (5): 819-28
76. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1108-16
77. Pearlman DS, Peden D, Condemi JJ, et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 2004; 41 (8): 797-806
78. Busse WW, Shah SR, Somerville L, et al. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J Allergy Clin Immunol 2008 Jun; 121 (6): 1407-14
79. Bateman ED, Jacques L, Goldfrad C, et al. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006 Mar; 117 (3): 563-70
80. Koenig SM, Ostrom N, Pearlman D, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50mcg Diskus are ''stepped-down''. J Asthma 2008 Oct; 45 (8): 681-7
81. You-Ning L, Humphries M, Du X, et al. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. Int J Clin Pract 2005 Jul; 59 (7): 754-9
82. Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 (J.g twice daily) when administered via a chloro-fluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001 Feb; 95: 136-46
83. van Noord JA, Lill H, Carrillo Diaz T, et al. Clini- cal equivalence of a salmeterol/fluticasone propionate combination product (50/500 (J.g) delivered via a chloro-fluorocarbon-free metered-dose inhaler with the Diskus™ in patients with moderate to severe asthma. Clin Drug Invest 2001; 21 (4): 243-55
84. Bracamonte T, Schauer U, Emeryk A, et al. Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the Diskus™ or pressurised metered-dose inhaler in children with asthma. Clin Drug Invest 2005; 25 (1): 1-11
85. Bateman ED, Bousquet J, Keech ML, et al. The correlation between asthma control and health status: the GOAL study. Eur Respir J 2007 Jan; 29 (1): 56-63
86. Price DB, Williams AE, Yoxall S. Salmeterol/fluticasone stable-dose treatment compared with formoterol/ budesonide adjustable maintenance dosing: impact on health-related quality of life. Respir Res 2007; 8: 46
87. O'Connor RD, Patrick DL, Parasuraman B, et al. Patient satisfaction during treatment with adjustable-dose budeso-nide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI), fixed-dose BUD/FM pMDI, and fixed-dose fluticasone/salmeterol dry powder inhaler (FP/SM DPI) [abstract plus poster no. A13]. Am J Respir Crit Care Med 2008 May; 177: 609
88. O'Connor RD, Gilmore AS, Manjunath R, et al. Com- paring outcomes in patients with persistent asthma: a registry of two therapeutic alternatives. Curr Med Res Opin 2006 Mar; 22 (3): 453-61
89. Sorkness CA, Lemanske RF, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007 Jan; 119 (1): 64-72
90. Cowie RL, Boulet LP, Keith PK, et al. Tolerability of a salmeterol xinafoate/fluticasone propionate hydro-fluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study. Clin Ther 2007 Jul; 29 (7): 1390-402
91. Malone R, LaForce C, Nimmagadda S, et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005 Jul; 95 (1): 66-71
92. Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial. Chest 2006 Jan; 129 (1): 15-26
93. American College of Allergy, Asthma and Immunology. Guidelines for the diagnosis and management of asthma [online]. Available from URL: http://www.acaai.org/member/Practice-Resources/guidelines.htm [Accessed 2009 Jun 12]
94. Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/ fluticasone propionate combination: a pharmacoeco-nomic review of its use in the management of asthma. Pharmacoeconomics 2003; 21 (13): 951-89
95. Briggs AH, Bousquet J, Wallace MV, et al. Cost-effective- ness of asthma control: an economic appraisal of the GOAL study. Allergy 2006 May; 61 (5): 531-6
96. Borker R, Emmett A, Jhingran P, et al. Determining economic feasibility of fluticasone propionate-salmeterol vs mon-telukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Ann Allergy Asthma Immunol 2005 Aug; 95 (2): 181-9
97. Johansson G, Andreasson EB, Larsson PE, et al. Cost ef- fectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeco-nomics 2006; 24 (7): 695-708
98. Miller E, Sears MR, McIvor A, et al. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Can Respir J 2007 Jul; 14 (5): 269-75
99. Shih Y-CT, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics 2007; 25 (7): 577-90
100. Doull I, Price D, Thomas M, et al. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Curr Med Res Opin 2007 May; 23 (5): 1147-59
101. Rawlins MD, Culyer AJ. National Institute for Clini- cal Excellence and its value judgments. BMJ 2004; 329: 224-7
102. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2008 May, revised 2009 [online]. Available from URL: http://www.sign.ac.uk/pdf/sign101.pdf [Accessed 2009 Jun 12]
103. Chapman KR, Boulet LP, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31 (2): 320-5
104. Bellamy D, Harris T. Poor perceptions and expectations of asthma control: results of the International Control of Asthma Symptoms (ICAS) survey of patients and general practitioners. Prim Care Respir J 2005; 14: 252-8
105. Haughney J, Barnes G, Partridge M, et al. The Living & Breathing Study: a study of patients' views of asthma and its treatment. Prim Care Respir J 2004; 13: 28-35
106. Koenig SM, Murray JJ, Wolfe J, et al. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? Respir Med 2008; 102: 665-73
107. Lasserson TJ, Cates CJ, Ferrara G, et al. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2008; (3): CD004106
108. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007 Mar; 29 (3): 587-95
109. Lundback B, Dahl R. Assessment of asthma control and its impact on optimal treatment strategy. Allergy 2007 Jun; 62 (6): 611-9
110. Katz PP, Yelin EH, Eisner MD, et al. Perceived control of asthma and quality of life among adults with asthma. Ann Allergy Asthma Immunol 2002; 89 (3): 251-8
111. Delea TE, Hagiwara M, Stanford RH, et al. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clin Ther 2008 Mar; 30 (3): 560-71